Skip to content
The Policy VaultThe Policy Vault

OriahnnUnited Healthcare

Uterine fibroids (leiomyomas) with heavy menstrual bleeding

Preferred products

  • estrogen/progestin contraceptive (e.g. Loestrin FE)
  • progestin-releasing intrauterine device (e.g. Mirena)
  • progestin-only contraceptive [e.g., norethindrone (generic Micronor)]

Initial criteria

  • Diagnosis of uterine fibroids (leiomyomas)
  • Used for the management of heavy menstrual bleeding
  • Failure after a three-month trial, contraindication, or intolerance to ONE of the following: estrogen/progestin contraceptive (e.g. Loestrin FE), progestin-releasing intrauterine device (e.g. Mirena), or progestin-only contraceptive [e.g., norethindrone (generic Micronor)]
  • Prescribed by or in consultation with an Obstetrics/Gynecologist (OB/GYN) OR reproductive endocrinologist

Reauthorization criteria

  • Documentation of positive clinical response to therapy
  • Impact to bone mineral density has been considered
  • Treatment duration has not exceeded a total of 24 months

Approval duration

12 months (up to a maximum total treatment duration of 24 months)